Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider Eric Warren sold 7,437 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $25.98, for a total value of $193,213.26. Following the completion of the transaction, the insider owned 38,400 shares in the company, valued at approximately $997,632. This represents a 16.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eric Warren also recently made the following trade(s):
- On Tuesday, July 21st, Eric Warren sold 7,438 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.87, for a total transaction of $199,859.06.
- On Friday, June 26th, Eric Warren sold 104,124 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $25.90, for a total transaction of $2,696,811.60.
Mineralys Therapeutics Stock Performance
MLYS opened at $26.34 on Wednesday. Mineralys Therapeutics, Inc. has a 1-year low of $14.53 and a 1-year high of $47.65. The company has a market cap of $2.33 billion, a price-to-earnings ratio of -6.21 and a beta of 0.68. The company's fifty day moving average price is $26.82 and its two-hundred day moving average price is $27.23. The company has a current ratio of 34.46, a quick ratio of 34.46 and a debt-to-equity ratio of 0.18.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($2.30). On average, analysts expect that Mineralys Therapeutics, Inc. will post -4.45 EPS for the current fiscal year.
Institutional Investors Weigh In On Mineralys Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Navalign LLC purchased a new stake in Mineralys Therapeutics during the 4th quarter valued at about $33,000. KBC Group NV bought a new stake in Mineralys Therapeutics in the first quarter valued at approximately $33,000. Royal Bank of Canada lifted its position in Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company's stock valued at $56,000 after purchasing an additional 1,107 shares during the last quarter. FNY Investment Advisers LLC boosted its stake in shares of Mineralys Therapeutics by 400.0% during the second quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company's stock valued at $67,000 after purchasing an additional 2,000 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its stake in shares of Mineralys Therapeutics by 1,845.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company's stock valued at $76,000 after purchasing an additional 1,993 shares during the period. Institutional investors own 84.46% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on MLYS shares. Jefferies Financial Group restated a "hold" rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. HC Wainwright reiterated a "buy" rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut shares of Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Finally, Zacks Research downgraded Mineralys Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Thursday, August 13th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $49.33.
Get Our Latest Analysis on MLYS
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
